Cusatuzumab is a human alphaCD70 monoclonal antibody. Cusatuzumab shows cytotoxicity activity with enhanced antibody-dependent cellular. Cusatuzumab reduces leukemia stem cells (LSCs) and triggers gene signatures related to myeloid differentiation and apoptosis. Cusatuzumab has the potential for the research of Acute myeloid leukemia (AML).
Purity:
>98.0%
CAS Number:
[1864871-20-4]
Target:
Apoptosis
* VAT and and shipping costs not included. Errors and price changes excepted